Abstract
The delivery of cancer chemotherapy is often non-optimal because of dose reductions and delays related to various toxic effects. These result in a decrease of the dose intensity as well as of the relative dose intensity of a given regimen compared to a reference protocol. In retrospective studies, such modifications have been shown to negatively influence the therapeutic results in many clinical situations. The ability of haematopoietic growth factors to reduce chemotherapy-related neutropenia and its associated infectious complications allows better dose-on-time delivery of the chemotherapeutic drugs. The potential therapeutic impact of this effect remains to be determined in prospective studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
